tbuckley/cabot-search huggingface dataset:
Abstract 18549: Cardiac MR and CT Virtual Angioscopy Demonstrate Normal Coronary Ostial Morphology in Children With Anomalous Left Coronary Artery With Intraseptal Course
Authors: Julie A Brothers, Whitehead K Kevin, Paul M Weinberg, Stephen M Paridon, Mark A Fogel, Matthew A Harris
Journal: Circulation (2013)

Background: Anomalous left coronary artery from the right sinus of Valsalva (ALCA) with intraseptal course is generally considered benign but is often confused on imaging studies with the potentially lethal interarterial, intramural ALCA with associated slit-like orifice. The clinical significance differs between the two subtypes and it is important to differentiate them in order to avoid unnecessary surgical exploration. Limited data exist on intraseptal ALCA in the pediatric population. Methods: Medical records were retrospectively reviewed on fifteen pediatric patients diagnosed with ALCA between 11/2009 and 3/2013. We also evaluated their coronary artery origins and courses using cardiac magnetic resonance or computed tomography imaging on each patient and virtual angioscopy for three-dimensional assessment of coronary ostial morphology. Results: Patients were 5-18 years at diagnosis; seven (67%) were male. The right and left coronary origins arose from the right sinus of Valsalva as a common origin (N=9) or as a single coronary artery (N=6). Thirteen had an anomalous intraseptal left main coronary; two had anomalous left anterior descending with retroaortic circumflex coronary artery. Anomalous coronary ostia were round without evidence of stenosis on all studies (Figure). Echocardiography identified the anomalous vessel but was neither able to describe the intraseptal ALCA course nor directly visualize or confirm a normal ostium in any patient. Conclusions: Using cardiac magnetic resonance or computed tomography imaging, we demonstrate the anomalous coronary course and confirm round coronary ostia without ostial stenosis in our pediatric cohort with intraseptal ALCA. These data provide the basis for understanding the benign clinical course of intraseptal ALCA, differentiating it from the potentially lethal interarterial, intramural ALCA, and avoiding unnecessary surgical exploration.
Spontaneous and Radiation-Induced Pituitary Adenomas of Mice&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Arthur C. Upton, Jacob Furth
Journal: JNCI Journal of the National Cancer Institute (1955)

Spontaneous and Radiation-Induced Pituitary Adenomas of Mice Arthur C. Upton, Arthur C. Upton Biology Division, Oak Bidge National Laboratory, Oak Ridge, Tenn. Search for other works by this author on: Oxford Academic PubMed Google Scholar Jacob Furth Jacob Furth Biology Division, Oak Bidge National Laboratory, Oak Ridge, Tenn. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue 4, February 1955, Pages 1005–1021, https://doi.org/10.1093/jnci/15.4.1005 Published: 01 February 1955 Article history Received: 15 October 1954 Published: 01 February 1955
GM-CSF + INF-alpha induce a graft-versus-leukemia effect in BMT patients with relapsed AML and ALL
Authors: M. Arellano, E. K. Waller
Journal: Journal of Clinical Oncology (2004)

6634 Background: Relapse of acute leukemia following allogeneic hematopoietic progenitor cell transplantation (HPCT) has a poor prognosis. Second HPCT and donor leukocyte infusions have significant toxicity with limited effectiveness. GM-CSF and Interferon-alpha (IFN) activate dendritic cells and induce leukemia cells to express co-stimulatory molecules and enhance allo-antigen presentation, potentially inducing graft-versus-leukemia effects. We hypothesized GM-CSF and IFN induce anti-leukemic effects in patients with relapsed acute leukemia. Methods: We performed a single institution retrospective study of 97 patients with AML or ALL relapsed after allogeneic HPCT. The dose and duration of cytokines, toxicities, response, and post-relapse survival were analyzed. Overall survival rates of cytokine-treated patients were compared with relapsed leukemia patients who did not receive cytokine immunotherapy. Results: Six patients received GM-CSF and IFN injections following the diagnosis of ALL or AML relapsed after allogeneic HPCT. The median dose of GM-CSF was 500 ug administered 3 times per week (median of 6 doses). The median dose of IFN was 3 million units administered 1–3 times per week (median of 6 doses). Four of the 6 patients (67%) exhibited a pathologic or hematologic remission with an average response of 3.3 mos. (range 6 wks. to 12 mos.) Toxicities included malaise, myalgias, and fever. GVHD was documented in 4 out of the 6 patients, and occurred at a median of 6 weeks after beginning cytokine immunotherapy. The median survival of cytokine-treated patients was 130 days with 3/6 patients remaining alive at a median follow-up of 373 days. Two of 3 surviving patients remain without evidence of disease on no immunosuppressive drugs. Cytokine-treated patients had better survival compared to 91 non-cytokine-treated patients with relapsed ALL or AML (median survival of 52 days, one-year survival of 8%, p=0.02). Conclusions: The administration of GM-CSF and IFN may induce remissions in patients with acute leukemia who have relapsed after allogeneic HPCT. Further studies to evaluate the optimal dosing schedule and duration of therapy should be pursued. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen Amgen Amgen
Frequency, Clinical Associations, and Prognostic Significance Of Spliceosome Mutations In Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia
Authors: Young-Uk Cho, Hyun-Sook Chi, Sang Hyuk Park, Young Jin Kim, Seongsoo Jang, Eul-Ju Seo, Chan-Jeoung Park, Dae-Young Kim, Jung-Hee Lee, Je-Hwan Lee, Kyoo-Hyung Lee, Kyung Nam Koh, Ho Joon Im, Jong Jin Seo, Young-Mi Park, Jong-Keuk Lee
Journal: Blood (2013)
Stillbirths: ending preventable deaths by 2030
Authors: Luc de Bernis, Mary V Kinney, William Stones, Petra ten Hoope-Bender, Donna Vivio, Susannah Hopkins Leisher, Zulfiqar A Bhutta, Metin Gülmezoglu, Matthews Mathai, Jose M Belizán, Lynne Franco, Lori McDougall, Jennifer Zeitlin, Address Malata, Kim E Dickson, Joy E Lawn
Journal: The Lancet (2016)
RNA-Directed DNA Polymerase Systems: Not Necessarily Transforming Rous Viruses<xref ref-type="fn" rid="FN1">1</xref><xref ref-type="fn" rid="FN2">2</xref>
Authors: Howard M. Temin
Journal: JNCI Journal of the National Cancer Institute (1972)

Rous sarcoma virus is the prototype RNA tumor virus. It provides a basis for work with other RNA tumor viruses, including mammary tumor virus. Thus far, however, Rous sarcoma virus and mammary tumor virus have been shown to share only a few properties. Caution should be used before concluding that all RNA viruses that contain RNA-directed DNA polymerase systems are transforming viruses. In addition, the presence of a ribonuclease-sensitive DNA polymerase system in a particle does not necessarily identify it as a virus.
Pharmacologic-guided trial of sequential methotrexate and thioguanine in children with advanced malignancies.
Authors: C T Tan, N Wollner, T Trippett, E Goker, W P Tong, A Kheradpour, P A Meyers, K M VanSyckle, L Guarino, Y Elisseyeff
Journal: Journal of Clinical Oncology (1994)

PURPOSE Based on in vitro studies that have shown synergistic effects of sequential administration of methotrexate (MTX) and thioguanine (6-TG), we conducted a pharmacologically guided trial of sequential MTX and 6-TG to determine the following: (1) the maximum-tolerated dose (MTD) of 6-TG; (2) the nature of the dose-limiting toxicity; and (3) the modulation effect of MTX on 6-TG given by this sequence and schedule. PATIENTS AND METHODS Thirty-one children with advanced malignancies (acute leukemia, n = 10; lymphoma n = 10; and solid tumors, n = 11) were treated weekly for 3 weeks with a 2-week rest; treatment consisted of a fixed dose of MTX (30 mg/m2 over 24 hours) followed by a 2-hour infusion of 6-TG in escalating doses. RESULTS Measurement of plasma MTX, 6-TG, and mononuclear 5-phosphoribosyl-1-pyrophosphate (PRPP) levels indicates that the desired biochemical modulation and serum levels were achieved. Nonhematologic toxicities were mild and the dose-limiting toxicity was bone marrow depression. A 300-mg/m2 dose of 6-TG with MTX is considered the MTD. Responses were noted in patients with lymphoma. CONCLUSION Encouraging antitumor effects were produced with this regimen in heavily pretreated patients with lymphoma, particularly Hodgkin's disease (HD). The durations of responses were 17, 13+, 12, 9, and 7+ months. A phase II trial of the MTX/6-TG combination is warranted for the treatment of relapsed lymphoma.
Response to: ‘A relationship between extracapsular involvement and response to steroid treatment in polymyalgia rheumatica: too soon to conclude?’ by Yang <i>et al</i>
Authors: Sarah L Mackie, Dennis G McGonagle
Journal: Annals of the Rheumatic Diseases (2016)

We thank Yang et al 1 for their comments on our whole body MRI study in patients with polymyalgia rheumatica (PMR). Our previous work in PMR revealed inflammatory changes outside the joint cavity, or ‘extracapsular pattern disease’, in both the shoulder and the hand.2 ,3 In a preliminary analysis of four non-contrast whole-body MRIs in the present cohort, we saw an identical pattern of disease in PMR and consequently developed the scoring system described. In addition to scoring the individual sites semi-quantitatively, we also classified the overall pattern as ‘extracapsular’ or not, using visual pattern recognition. This Gestalt- based classification was not derived directly from any of the individual site scores.

Subsequently, after unblinding of clinical diagnosis, we derived an …
WASKIA INTESTINALIS: ITS CULTIVATION AND CYST FORMATION
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dose dense accelerated BEP for metastatic germ cell tumour: A phase II clinical trial
Authors: M. V. Williams, Y. Rimmer, N. Upton, J. Chester, J. Shamash, J. White
Journal: Journal of Clinical Oncology (2008)

16077 Background: Granulocyte colony-stimulating factor (G-CSF) permits shorter cycle intervals and increased dose density in breast cancer, small cell lung cancer and lymphoma. We report the first phase II study to assess the tolerability and toxicity of a dose dense accelerated BEP regimen in patients with germ cell tumours. Methods: Patients (pts) from 4 UK centres with intermediate and high risk metastatic germ cell tumour according to the IGCCG criteria entered this study. Pts were treated with 4 cycles every 14 days (d) of Cisplatin (50 mg/m2) d1–2, Etoposide (165 mg/m2) d1–3, Bleomycin (30,000 IU, 3 doses/cycle) at 4–6 d intervals and Pegfilgrastin (Neulasta, Amgen 6 mg sc) d4. The planned dose-intensity for each drug was 1.5 compared to standard BEP. Results: 12 of 20 planned pts were recruited 2004–2007. 9 pts had intermediate risk disease and 3 had high risk disease. Ten of 12 pts completed 4 cycles of treatment as planned. Complete response after chemotherapy was achieved in 1 pt (10%) and after chemotherapy plus surgery in 5 pts (42%). Four pts (33%) with partial response normalized their marker levels; 2 (17%) failed treatment. Two patients (not treatment failures) reverted to standard BEP after 2 cycles due to grade 3 mucositis and grade 4 haematological toxicity. Analysis of 44 cycles shows that the percentage with grade 3 or 4 haematological toxicity was: thrombocytopenia 14% and 7%; neutropenia 14% and 18%; and febrile neutropenia 11%. EDTA clearance pre-treatment was 143 (mean, range: 118–207) and post-treatment was 90 (mean, range: 72–136) Median follow-up is 16 months (3.7–38.1) and estimated 2 year progression free survival is 73%. 9/12 pts remain disease-free with no recorded deaths. Conclusions: The elective use of G-CSF permits a 50% increase in the dose density of BEP for the majority of patients. The potential for improved outcomes should now be assessed in a randomised study. No significant financial relationships to disclose.
Physiopathology of Nephrotic Edema: Role of Aldosterone
Authors: J GENEST
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gemcitabine and oxalipaltin (Gemox) in advanced/unresectable gall baldder cancer: A phase II study
Authors: A. Sharma, V. Raina, N. K. Shukla, S. V. Deo
Journal: Journal of Clinical Oncology (2006)

14027 Background: Adenocarcinoma of gall bladder is common in females in northern part of India with rising incidence. In Delhi incidence is 5.5 per 1,00,000 population in females (4 th most common cancer in females after breast, cervix, and ovary). Majority of patients present in unresectable stage and are offered palliative treatment by placing a stent and/or using chemotherapy. Gemcitabine and Oxaliplatin as single agents or in combinations with others have shown some activity in adenocarcinoma of pancreas, gall bladder, and biliary tracts. There is in vitro evidence about synergism between gemcitabine and oxalipaltin. To investigate efficacy of this combination in advanced/ inoperable gall bladder cancer this study was started. Method: A phase II study. Eligible patients were started on Gemcitabine and oxaliplatin combination as: Inj Gemcitabine 900 mg/m 2 IV 30 minutes infusion day 1 and 8, Inj Oxaliplatin 80 mg/m 2 2 hours infusion in Dextrose 5% Day 1 and 8 All every 3 weeks. For a maximum of 6 cycles/ disease progression which ever is early. Protocol was approved by local ethics committee. Results: Thirty two recurrent/ unresectable patients, twenty two of them females, with an age range of 31–72 years (median 48 years) were enrolled for the study after obtaining written consent. With median of 3 total of 98 cycles (range 1–6) have been delivered. 3 patients received 6 cycles and another 8 are at various stages of therapy. Grade III/IV toxicity was seen in 4 patient; no toxic death. Responses have been assessed on intent to treat basis using RECIST criteria: CR 2 (6.3%) including one pathological, PR 3 (9.4%), SD 10 (31.3%), 13 (40.6%) progressed (PD) on chemotherapy, and in 4 (12.5%) patients response evaluation is being done. Even in a worst case scenario about 16% patient had documented response and another 31% stable disease. On follow up 18 (56.2%) patients have died. Median survival is 6 months and 10 patients survived more than 6 months and 10 months survival is 12% (4 patients). Updated results will be presented during meeting. Conclusion: This combination is feasible, well tolerated and may be viable option in treatment of such patients where otherwise median survival is about 3 months. These results warrant further evaluation in a large trial. No significant financial relationships to disclose.
Lung function and airway obstruction: associations with circulating markers of cardiac function and incident heart failure in older men—the British Regional Heart Study
Authors: S Goya Wannamethee, A Gerald Shaper, Olia Papacosta, Lucy Lennon, Paul Welsh, Peter H Whincup
Journal: Thorax (2016)

<h3>Aims</h3> The association between lung function and cardiac markers and heart failure (HF) has been little studied in the general older population. We have examined the association between lung function and airway obstruction with cardiac markers N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) and risk of incident HF in older men. <h3>Methods and results</h3> Prospective study of 3242 men aged 60–79 years without prevalent HF or myocardial infarction followed up for an average period of 13 years, in whom 211 incident HF cases occurred. Incident HF was examined in relation to % predicted FEV1 and FVC. The Global Initiative on Obstructive Lung Diseases spirometry criteria were used to define airway obstruction. Reduced FEV1, but not FVC in the normal range, was significantly associated with increased risk of HF after adjustment for established HF risk factors including inflammation. The adjusted HRs comparing men in the 6–24th percentile with the highest quartile were 1.91 (1.24 to 2.94) and 1.30 (0.86 to 1.96) for FEV1 and FVC, respectively. FEV1 and FVC were inversely associated with NT-proBNP and cTnT, although the association between FEV1 and incident HF remained after adjustment for NT-proBNP and cTnT. Compared with normal subjects (FEV1/FVC ≥0.70 and FVC≥80%), moderate or severe (FEV1/FVC &lt;0.70 and FEV1 &lt;80%) airflow obstruction was independently associated with HF ((adjusted relative risk 1.59 (1.08 to 2.33)). Airflow restriction (FEV1/FVC ≥0.70 and FVC &lt;80%) was not independently associated with HF. <h3>Conclusions</h3> Reduced FEV1 reflecting airflow obstruction is associated with cardiac dysfunction and increased risk of incident HF in older men.
1249G&gt;A polymorphism of <i>ABCC2</i> (MRP2) is associated with altered gene expression in human liver
Authors: D. L. Kroetz, W. Liu, T. D. Nguyen, B. M. Zwecker, J. Ramirez, F. Innocenti, M. J. Ratain
Journal: Journal of Clinical Oncology (2006)

13072 Background: MRP2, encoded by ABCC2, is an ATP-binding cassette transporter that plays a critical role in the biliary elimination of various drugs and xenobiotics. Although SNPs in this gene have been identified and reported, their functions are not fully understood. T he purpose of this study was to evaluate the effect of polymorphisms/haplotypes of the ABCC2 gene on its mRNA expression in human liver. Methods: Two hundred human liver samples were genotyped for the following polymorphisms: −1549G&gt;A, −1019A&gt;G, −24C&gt;T, 1249G&gt;A (V417I), −34T&gt;C (intron 27) and 3972C&gt;T. Haplotypes and diplotypes were predicted and assigned to each individual. Haplotype-specific expression was then tested using 3972C&gt;T and 1249G&gt;A as markers. Heterozygous Caucasian samples for 3972C&gt;T and 1249G&gt;A were selected and the two SNPs were genotyped in the PCR and/or RT-PCR products from both DNA and the corresponding mRNA. The minisequencing-based SNaPshot method was used to genotype and quantify the expression level of each allele. The relative expression of both alleles in the mRNA was normalized to that in the DNA. Results: There is no haplotype-specific expression discriminated by the 3972C&gt;T polymorphism. However, when using 1249G&gt;A as a marker, the haplotypes containing the 1249A allele had significantly higher mRNA levels when compared with haplotypes containing the 1249G allele (one sample t test, p &lt; 0.001, n = 37). Conclusions: The 1249G&gt;A substitution in the ABCC2 gene may be associated with gene expression in human liver. Significant variability of the relative expression of ABCC2 in the population suggests that other functional polymorphisms and environmental factors may also be involved in the regulation of ABCC2 expression. No significant financial relationships to disclose.
Abelson Murine Leukemia Virus-Induced Thymic Lymphomas: Transformation of a Primitive Lymphoid Precursor<xref ref-type="fn" rid="FN2">2</xref>
Authors: E D'Andrea, D Saggioro, E Fleissner, L Chieco-Bianchi
Journal: JNCI Journal of the National Cancer Institute (1987)

For the investigation of whether Abelson murine leukemia virus (A-MuLV) is able to transform in vivo lymphocytes other than those of the B-cell lineage, newborn BALB/c and C57BL/6 mice were given an injection of A-MuLV directly into the thymus. Thymic lymphomas appeared with a short latent period of 4–5 weeks in BALB/c mice and 8 weeks in C57BL/6 mice. Cell lines derived from some thymic lymphomas presented a very immature phenotype and did not express cellular markers of either T-cells (Thy 1.2, Lyt 1.2, and Lyt 2.2) or B-cells (cytoplasmic IgM) even after treatment with several differentiation inducers. Molecular analysis showed that T-cell receptor (TCR) beta chain genes were never rearranged; in one case only, rearrangement of TCR gamma chain genes could be demonstrated, confirming the immaturity of the presumptive T-cell lines studied. Furthermore, the cell lines consistently carried diversity (D)-joining (J) but not variable (V)-D-J rearrangements of the immunoglobulin heavy chain genes. On the whole, these findings suggest that following intrathymic A-MuLV injection neoplastic transformation does involve lymphocytes possibly of T-cell lineage, at a very early stage of differentiation.